ArticleCells2019
Biochemical Differences in Cerebrospinal Fluid between Secondary Progressive and Relapsing⁻Remitting Multiple Sclerosis.
Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.Frontiers in immunology · 2022Pooled it
- Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.Journal of neurology · 2021Pooled it
- Integrated multi-omics analysis identifies microbial and metabolic signatures and drivers of CNS autoimmunity.mSystems · 2026Article
- Untargeted and Targeted Cerebrospinal Fluid Neurometabolomics via Chromatography-Mass Spectrometry-Based Methods.Molecules (Basel, Switzerland) · 2026Review
- [Application of chromatography-mass spectrometry in the clinical analysis of multiple sclerosis].Se pu = Chinese journal of chromatography · 2026Review
- M cell-dependent commensal uptake confers encephalitogenic phenotypes on γδT17 cells in Peyer's patches.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Integrated multi-omics analysis identifies microbial and metabolic signatures and drivers of CNS autoimmunity.bioRxiv : the preprint server for biology · 2026Article
- 3D chromatin-based variant-to-gene maps across 57 human cell types reveal the cellular and genetic architecture of autoimmune disease susceptibility.Genome biology · 2025Article
- Blood metabolomics improves prediction of central nervous system damage in multiple sclerosis.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Kynurenine Pathway Modulation by Exercise in Multiple Sclerosis: Implications for Neuroprotection and Inflammation.Cellular and molecular neurobiology · 2025Review
- Article
- Cerebrospinal fluid metabolomics, lipidomics and serine pathway dysfunction in myalgic encephalomyelitis/chronic fatigue syndroome (ME/CFS).Scientific reports · 2025Article
- Recent Advances in Metabolomics and Lipidomics Studies in Human and Animal Models of Multiple Sclerosis.Metabolites · 2024Review
- Modulation of multiple sclerosis risk and pathogenesis by the gut microbiota: Complex interactions between host genetics, bacterial metabolism, and diet.Immunological reviews · 2024Review
- Integrating Network Pharmacology and Metabolomics to Reveal the Immunomodulatory Mechanism of EthnomedicineDrug design, development and therapy · 2024Article
- New insights into healthy ageing, inflammageing and frailty using metabolomics.Frontiers in aging · 2024Review
- Disease phenotype prediction in multiple sclerosis.iScience · 2023Article
- Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis.Frontiers in genetics · 2023Review
- Lactobacillus reuteri tryptophan metabolism promotes host susceptibility to CNS autoimmunity.Microbiome · 2022Article
- How Microbiota-Derived Metabolites Link the Gut to the Brain during Neuroinflammation.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To better understand the pathophysiological differences between secondary progressive multiple sclerosis (SPMS) and relapsing-remitting multiple sclerosis (RRMS), and to identify potential biomarkers of disease progression, we applied high-resolution mass spectrometry (HRMS) to investigate the metabolome of cerebrospinal fluid (CSF). The biochemical differences were determined using partial least squares discriminant analysis (PLS-DA) and connected to biochemical pathways as well as associated to clinical and radiological measures. Tryptophan metabolism was significantly altered, with perturbed levels of kynurenate, 5-hydroxytryptophan, 5-hydroxyindoleacetate, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.